Laboratory Medicine ›› 2024, Vol. 39 ›› Issue (12): 1219-1223.DOI: 10.3969/j.issn.1673-8640.2024.12.015
Previous Articles Next Articles
SONG Beiling1, WU Jiong2(
), HU Jiahua2, WANG Yufei3(
)
Received:2024-01-24
Revised:2024-07-26
Online:2024-12-30
Published:2025-01-06
CLC Number:
SONG Beiling, WU Jiong, HU Jiahua, WANG Yufei. Influence of common hemoglobin variants on different glycated hemoglobin determination systems[J]. Laboratory Medicine, 2024, 39(12): 1219-1223.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2024.12.015
| 序号 | 变异体名称 | 突变链 | 突变位点 | 样本数量 |
|---|---|---|---|---|
| 1 | Hb G-Coushatta | β链 | 22 GAA→GCA | 42 |
| 2 | Hb G-Taipei | β链 | 22 GAA→GGA | 28 |
| 3 | Hb J-Bangkok | β链 | 56 GGC→GAC | 13 |
| 4 | Hb D-Los Angeles | β链 | 121 GAA→CAA | 10 |
| 5 | Hb Pyrgos | β链 | 83 GGC→GAC | 10 |
| 6 | Hb Q-Thailand | α链 | 74 GAC→CAC | 9 |
| 7 | Hb Queens | α链 | 34 CTG→CGG | 7 |
| 8 | Hb Quong Sze | α链 | 125 CTG→CCG | 5 |
| 9 | Hb C | β链 | 6 GAG→AAG | 5 |
| 10 | Hb E | β链 | 26 GAG→AAG | 6 |
| 11 | Hb S | β链 | 6 GAG→GTG | 6 |
| 序号 | 变异体名称 | 突变链 | 突变位点 | 样本数量 |
|---|---|---|---|---|
| 1 | Hb G-Coushatta | β链 | 22 GAA→GCA | 42 |
| 2 | Hb G-Taipei | β链 | 22 GAA→GGA | 28 |
| 3 | Hb J-Bangkok | β链 | 56 GGC→GAC | 13 |
| 4 | Hb D-Los Angeles | β链 | 121 GAA→CAA | 10 |
| 5 | Hb Pyrgos | β链 | 83 GGC→GAC | 10 |
| 6 | Hb Q-Thailand | α链 | 74 GAC→CAC | 9 |
| 7 | Hb Queens | α链 | 34 CTG→CGG | 7 |
| 8 | Hb Quong Sze | α链 | 125 CTG→CCG | 5 |
| 9 | Hb C | β链 | 6 GAG→AAG | 5 |
| 10 | Hb E | β链 | 26 GAG→AAG | 6 |
| 11 | Hb S | β链 | 6 GAG→GTG | 6 |
| 检测系统 | Hb G-Coushatta | Hb G-Taipei | Hb J-Bangkok | Hb D-Los Angeles | Hb Pyrgos | Hb Q-Thailand | ||
|---|---|---|---|---|---|---|---|---|
| D-100 | ||||||||
| 干扰报警 | E-Window | E-Window | 不报警 | D-Window | 不报警 | S-Window | ||
| 异常峰位置/s | 27.10 | 27.23 | 28.31 | 66.77 | ||||
| 异常峰面积/% | 37.54 | 38.73 | 39.96 | 39.96 | ||||
| G8 | ||||||||
| 干扰报警 | 不报警 | 不报警 | 不报警 | H-VD | 不报警 | H-V1 | ||
| 异常峰位置/s | 1.01 | 1.16 | ||||||
| 异常峰面积/% | 29.00 | 75.10 | ||||||
| MQ-6000 | ||||||||
| 干扰报警 | 变异体报警 | 变异体报警 | 变异体报警 | 变异体报警 | 不报警 | 变异体报警 | ||
| 异常峰位置/s | 63.10 | 64.70 | 59.30 | 69.50 | 72.00 | |||
| 异常峰面积/% | 48.14 | 48.38 | 70.96 | 39.38 | 38.72 | |||
| MQ-8000 | ||||||||
| 干扰报警 | 变异体报警 | 变异体报警 | 变异体报警 | 变异体报警 | 不报警 | 不报警 | ||
| 异常峰位置/s | 57.80 | 57.90 | 54.50 | 62.80 | ||||
| 异常峰面积/% | 48.01 | 49.23 | 76.76 | 40.03 | ||||
| Variant Ⅱ | ||||||||
| 干扰报警 | E-D报警 | 不报警 | 不报警 | E-D报警 | 不报警 | S报警 | ||
| 异常峰位置/s | 1.85 | 1.91 | 1.98 | |||||
| 异常峰面积/% | 49.30 | 42.10 | 70.70 | |||||
| Capillarys 2 | ||||||||
| 干扰报警 | 未知峰报警 | 未知峰报警 | 未知峰报警 | 未知峰报警 | 未知峰报警 | 未知峰报警 | ||
| 异常峰位置/s | ||||||||
| 异常峰面积/% | 33.00 | 33.00 | 38.20 | 30.00 | 25.60 | 12.70 | ||
| 检测系统 | Hb Queens | Hb Quong Sze | Hb C | Hb E | Hb S | |||
| D-100 | ||||||||
| 干扰报警 | S-Window | 不报警 | C-Window | E-Window | S-Window | |||
| 异常峰位置/s | 28.85 | 30.00 | 27.10 | 28.00 | ||||
| 异常峰面积/% | 30.16 | 17.46 | 37.58 | 18.69 | ||||
| G8 | ||||||||
| 干扰报警 | H-V1 | 不报警 | H-V1 | 不报警 | H-V1 | |||
| 异常峰位置/s | 1.12 | 1.18 | 1.15 | |||||
| 异常峰面积/% | 9.20 | 14.60 | 16.00 | |||||
| MQ-6000 | ||||||||
| 干扰报警 | 不报警 | 不报警 | 变异体报警 | 变异体报警 | 变异体报警 | |||
| 异常峰位置/s | 84.10 | 62.10 | 71.50 | |||||
| 异常峰面积/% | 38.57 | 57.41 | 17.69 | |||||
| MQ-8000 | ||||||||
| 干扰报警 | 不报警 | 不报警 | 变异体报警 | 变异体报警 | 变异体报警 | |||
| 异常峰位置/s | 78.20 | 52.60 | 64.40 | |||||
| 异常峰面积/% | 18.76 | 55.51 | 19.36 | |||||
| 检测系统 | Hb Queens | Hb Quong Sze | Hb C | Hb E | Hb S | |||
| Variant Ⅱ | ||||||||
| 干扰报警 | 不报警 | 不报警 | 不报警 | 不报警 | S报警 | |||
| 异常峰位置/s | 1.95 | |||||||
| 异常峰面积/% | 19.50 | |||||||
| Capillarys 2 | ||||||||
| 干扰报警 | 未知峰报警 | 未知峰报警 | 未知峰报警 | 未知峰报警 | 未知峰报警 | |||
| 异常峰位置/s | ||||||||
| 异常峰面积/% | 34.80 | 38.20 | 6.80 | 33.20 | 12.40 | |||
| 检测系统 | Hb G-Coushatta | Hb G-Taipei | Hb J-Bangkok | Hb D-Los Angeles | Hb Pyrgos | Hb Q-Thailand | ||
|---|---|---|---|---|---|---|---|---|
| D-100 | ||||||||
| 干扰报警 | E-Window | E-Window | 不报警 | D-Window | 不报警 | S-Window | ||
| 异常峰位置/s | 27.10 | 27.23 | 28.31 | 66.77 | ||||
| 异常峰面积/% | 37.54 | 38.73 | 39.96 | 39.96 | ||||
| G8 | ||||||||
| 干扰报警 | 不报警 | 不报警 | 不报警 | H-VD | 不报警 | H-V1 | ||
| 异常峰位置/s | 1.01 | 1.16 | ||||||
| 异常峰面积/% | 29.00 | 75.10 | ||||||
| MQ-6000 | ||||||||
| 干扰报警 | 变异体报警 | 变异体报警 | 变异体报警 | 变异体报警 | 不报警 | 变异体报警 | ||
| 异常峰位置/s | 63.10 | 64.70 | 59.30 | 69.50 | 72.00 | |||
| 异常峰面积/% | 48.14 | 48.38 | 70.96 | 39.38 | 38.72 | |||
| MQ-8000 | ||||||||
| 干扰报警 | 变异体报警 | 变异体报警 | 变异体报警 | 变异体报警 | 不报警 | 不报警 | ||
| 异常峰位置/s | 57.80 | 57.90 | 54.50 | 62.80 | ||||
| 异常峰面积/% | 48.01 | 49.23 | 76.76 | 40.03 | ||||
| Variant Ⅱ | ||||||||
| 干扰报警 | E-D报警 | 不报警 | 不报警 | E-D报警 | 不报警 | S报警 | ||
| 异常峰位置/s | 1.85 | 1.91 | 1.98 | |||||
| 异常峰面积/% | 49.30 | 42.10 | 70.70 | |||||
| Capillarys 2 | ||||||||
| 干扰报警 | 未知峰报警 | 未知峰报警 | 未知峰报警 | 未知峰报警 | 未知峰报警 | 未知峰报警 | ||
| 异常峰位置/s | ||||||||
| 异常峰面积/% | 33.00 | 33.00 | 38.20 | 30.00 | 25.60 | 12.70 | ||
| 检测系统 | Hb Queens | Hb Quong Sze | Hb C | Hb E | Hb S | |||
| D-100 | ||||||||
| 干扰报警 | S-Window | 不报警 | C-Window | E-Window | S-Window | |||
| 异常峰位置/s | 28.85 | 30.00 | 27.10 | 28.00 | ||||
| 异常峰面积/% | 30.16 | 17.46 | 37.58 | 18.69 | ||||
| G8 | ||||||||
| 干扰报警 | H-V1 | 不报警 | H-V1 | 不报警 | H-V1 | |||
| 异常峰位置/s | 1.12 | 1.18 | 1.15 | |||||
| 异常峰面积/% | 9.20 | 14.60 | 16.00 | |||||
| MQ-6000 | ||||||||
| 干扰报警 | 不报警 | 不报警 | 变异体报警 | 变异体报警 | 变异体报警 | |||
| 异常峰位置/s | 84.10 | 62.10 | 71.50 | |||||
| 异常峰面积/% | 38.57 | 57.41 | 17.69 | |||||
| MQ-8000 | ||||||||
| 干扰报警 | 不报警 | 不报警 | 变异体报警 | 变异体报警 | 变异体报警 | |||
| 异常峰位置/s | 78.20 | 52.60 | 64.40 | |||||
| 异常峰面积/% | 18.76 | 55.51 | 19.36 | |||||
| 检测系统 | Hb Queens | Hb Quong Sze | Hb C | Hb E | Hb S | |||
| Variant Ⅱ | ||||||||
| 干扰报警 | 不报警 | 不报警 | 不报警 | 不报警 | S报警 | |||
| 异常峰位置/s | 1.95 | |||||||
| 异常峰面积/% | 19.50 | |||||||
| Capillarys 2 | ||||||||
| 干扰报警 | 未知峰报警 | 未知峰报警 | 未知峰报警 | 未知峰报警 | 未知峰报警 | |||
| 异常峰位置/s | ||||||||
| 异常峰面积/% | 34.80 | 38.20 | 6.80 | 33.20 | 12.40 | |||
| 检测系统 | Hb G-Coushatta | Hb G-Taipei | Hb J-Bangkok | Hb D-Los Angeles | Hb Pyrgos | Hb Q-Thailand | Hb Queens | Hb Quong Sze | Hb C | Hb E | Hb S |
|---|---|---|---|---|---|---|---|---|---|---|---|
| cobas c513/例 | 42 | 38 | 13 | 10 | 10 | 9 | 7 | 5 | 5 | 6 | 6 |
| D-100 | |||||||||||
| r2值 | 0.97 | 0.96 | 0.80 | 1.00 | 0.01 | 0.59 | 0.99 | 0.99 | 1.00 | 0.99 | 0.99 |
| 不一致例数①/例 | 0 | 6 | 13 | 0 | 10 | 9 | 0 | 0 | 0 | 0 | 0 |
| G8 | |||||||||||
| r2值 | 0.91 | 0.90 | 0.97 | 0.97 | 0.80 | 0.94 | 0.95 | 0.87 | 1.00 | 0.82 | 1.00 |
| 不一致例数①/例 | 0 | 28 | 12 | 3 | 10 | 1 | 0 | 5 | 0 | 6 | 0 |
| MQ-6000 | |||||||||||
| r2值 | 0.98 | 0.70 | 0.88 | 0.99 | 0.32 | 0.86 | 0.64 | 0.73 | 0.99 | 1.00 | 0.99 |
| 不一致例数①/例 | 0 | 4 | 12 | 3 | 10 | 6 | 6 | 5 | 0 | 0 | 0 |
| MQ-8000 | |||||||||||
| r2值 | 1.00 | 0.97 | 0.98 | 0.98 | — | 1.00 | 0.81 | — | 0.99 | 1.00 | 0.99 |
| 不一致例数①/例 | 0 | 3 | 13 | 6 | 10 | 0 | 6 | 5 | 0 | 0 | 0 |
| Variant Ⅱ | |||||||||||
| r2值 | 0.75 | 0.74 | 0.97 | 0.99 | 0.94 | 0.92 | 0.89 | 1.00 | 0.88 | 0.93 | 1.00 |
| 不一致例数①/例 | 42 | 28 | 13 | 0 | 10 | 7 | 7 | 0 | 3 | 4 | 0 |
| Capillarys 2 | |||||||||||
| r2值 | 0.95 | 0.77 | 1.00 | 0.96 | 0.99 | 1.00 | 0.78 | 0.94 | 0.99 | 1.00 | 0.99 |
| 不一致例数①/例 | 0 | 5 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 |
| 检测系统 | Hb G-Coushatta | Hb G-Taipei | Hb J-Bangkok | Hb D-Los Angeles | Hb Pyrgos | Hb Q-Thailand | Hb Queens | Hb Quong Sze | Hb C | Hb E | Hb S |
|---|---|---|---|---|---|---|---|---|---|---|---|
| cobas c513/例 | 42 | 38 | 13 | 10 | 10 | 9 | 7 | 5 | 5 | 6 | 6 |
| D-100 | |||||||||||
| r2值 | 0.97 | 0.96 | 0.80 | 1.00 | 0.01 | 0.59 | 0.99 | 0.99 | 1.00 | 0.99 | 0.99 |
| 不一致例数①/例 | 0 | 6 | 13 | 0 | 10 | 9 | 0 | 0 | 0 | 0 | 0 |
| G8 | |||||||||||
| r2值 | 0.91 | 0.90 | 0.97 | 0.97 | 0.80 | 0.94 | 0.95 | 0.87 | 1.00 | 0.82 | 1.00 |
| 不一致例数①/例 | 0 | 28 | 12 | 3 | 10 | 1 | 0 | 5 | 0 | 6 | 0 |
| MQ-6000 | |||||||||||
| r2值 | 0.98 | 0.70 | 0.88 | 0.99 | 0.32 | 0.86 | 0.64 | 0.73 | 0.99 | 1.00 | 0.99 |
| 不一致例数①/例 | 0 | 4 | 12 | 3 | 10 | 6 | 6 | 5 | 0 | 0 | 0 |
| MQ-8000 | |||||||||||
| r2值 | 1.00 | 0.97 | 0.98 | 0.98 | — | 1.00 | 0.81 | — | 0.99 | 1.00 | 0.99 |
| 不一致例数①/例 | 0 | 3 | 13 | 6 | 10 | 0 | 6 | 5 | 0 | 0 | 0 |
| Variant Ⅱ | |||||||||||
| r2值 | 0.75 | 0.74 | 0.97 | 0.99 | 0.94 | 0.92 | 0.89 | 1.00 | 0.88 | 0.93 | 1.00 |
| 不一致例数①/例 | 42 | 28 | 13 | 0 | 10 | 7 | 7 | 0 | 3 | 4 | 0 |
| Capillarys 2 | |||||||||||
| r2值 | 0.95 | 0.77 | 1.00 | 0.96 | 0.99 | 1.00 | 0.78 | 0.94 | 0.99 | 1.00 | 0.99 |
| 不一致例数①/例 | 0 | 5 | 0 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 |
| [1] | American Diabetes Association. Standards of medical care in diabetes-2011[J]. Diabetes Care, 2011, 34(Suppl 1):S11-S61. |
| [2] | ELSAYED N A, ALEPPO G, ARODA V R, et al. Classification and diagnosis of diabetes:standards of care in diabetes-2023[J]. Diabetes Care, 2023,46:S19-S40. |
| [3] | LEE S T, KIM M S, CHOI D Y, et al. Incidence of variant hemoglobin(Hb)and increased fetal Hb concentrations and their effect on Hb A1c measurement in a Korean population[J]. Clin Chem, 2006, 52(7):1445-1446. |
| [4] | HARANO T. Hemoglobinopathy in Japan:detection and analysis[J]. Rinsho Byori, 1999, 47(3):215-323. |
| [5] | XU A, CHEN W, XIE W, et al. Hemoglobin variants in southern China:results obtained during the measurement of glycated hemoglobin in a large population[J]. Clin Chem Lab Med, 2020, 59(1):227-232. |
| [6] | WEN D M, XU S N, WANG W J, et al. Evaluation of the interference of hemoglobin variant J-Bangkok on glycated hemoglobin(HbA1c) measurement by five different methods[J]. Exp Clin Endocrinol Diabetes, 2017, 125(10):655-660. |
| [7] |
LITTLE R R, ROBERTS W L. A review of variant hemoglobins interfering with hemoglobin A1c measurement[J]. J Diabetes Sci Technol, 2009, 3(3):446-451.
DOI PMID |
| [8] | LIN C N, EMERY T J, LITTLE R R, et al. Effects of hemoglobin C,D,E,and S traits on measurements of HbA1c by six methods[J]. Clin Chim Acta, 2012, 413(7-8):819-821. |
| [9] | RHEA J M, KOCH D, RITCHIE J, et al. Unintended reporting of misleading Hb A(1c)values when using assays incapable of detecting hemoglobin variants[J]. Arch Pathol Lab Med, 2013, 137(12):1788-1791. |
| [10] | LITTLE R R, ROHLFING C L, HANSON S, et al. Effects of hemoglobin(Hb)E and HbD traits on measurements of glycated Hb(HbA1c) by 23 methods[J]. Clin Chem, 2008, 54(8):1277-1282. |
| [11] |
MONGIA S K, LITTLE R R, ROHLFING C L, et al. Effects of hemoglobin C and S traits on the results of 14 commercial glycated hemoglobin assays[J]. Am J Clin Pathol, 2008, 130(1):136-140.
DOI PMID |
| [1] | ZHOU Fangfang, GU Xuemei, WANG Wei, LIN Ming, WANG Lei. Establishment and application of main components of Huang-Lian-Jie-Du decoction based on high performance liquid chromatography [J]. Laboratory Medicine, 2024, 39(5): 468-473. |
| [2] | WANG Yajie, ZU Bailing, GAN Chenxin, WU Jiaoxiang, SHU Jie, HANG Chen, CHEN Minghui, LIN Fujun, HU Zhigang, HUANG Biao, SHENG Huiming. Identification of plasma differential peptids in PLA2R1-related membranous nephropathy patients [J]. Laboratory Medicine, 2023, 38(3): 223-229. |
| [3] | ZHENG Zhiyou, LI Xingzhao, XIE Yage. Changes and clinical significance of HbA1c,NT-proBNP,Hcy,SOD and TC levels in patients with diabetes cardiomyopathy [J]. Laboratory Medicine, 2023, 38(3): 282-286. |
| [4] | TANG Ningbo, LIU Guancai, LIU Xiaoyu, YANG Fengfan, GONG Zhimei, SUN Keqi. Establishment and evaluation for the determination of serum digitoxin as a candidate reference method [J]. Laboratory Medicine, 2022, 37(5): 456-462. |
| [5] | QU Yuanqing, ZHAO Fan, YE Ailian, LI Lifeng, ZHAO Haitao, LI Huizhen, LIANG Zhuohui, LI Liang. Relationship between plasma omentin-1 level and metabolic clearance rate in type 2 diabetes mellitus patients [J]. Laboratory Medicine, 2022, 37(1): 28-31. |
| [6] | YUE Daoyuan, CHEN Wei, LIAO Qing, YU Weiting, LI Huijun. Establishment and evaluation of Wuhan Glycohemoglobin Harmonization Program [J]. Laboratory Medicine, 2022, 37(1): 78-82. |
| [7] | ZHANG Lei, ZUO Ming, ZOU Wenbi, WANG Haoran, ZHANG Xiaoqing, DING Min. Method establishment of spot urine free NMN and MN by HPLC-ED and its clinical application [J]. Laboratory Medicine, 2021, 36(5): 524-529. |
| [8] | AN Chongwen, LI Haixia, JIAO Lili. Establishment of reference interval for the detection of serum protein electrophoresis by V8 Nexus high speed automated capillary electrophoresis apparatus [J]. Laboratory Medicine, 2021, 36(1): 8-12. |
| [9] | KANG Fengfeng, SHAN Zhiming, SONG Chao, XIA Xiaohua, CHEN Qian, LI Weixing. Comparability of glycated hemoglobin determination results with different determination systems using sigma metrics and robust algorithm [J]. Laboratory Medicine, 2020, 35(2): 168-172. |
| [10] | WANG Xiao, MI Xianqiang. Construction of a 16 channel label-free electrochemical immunosensor for glycated hemoglobin A1c detection [J]. Laboratory Medicine, 2019, 34(9): 835-840. |
| [11] | LIU Jie, SHI Xinrong, ZHOU Shufen, XU Hongmin, ZHANG Lei, LIU Shuye. Serum metabolins predicting acute myocardial infarction patients' outcome [J]. Laboratory Medicine, 2019, 34(5): 383-389. |
| [12] | LIU Wenbin, JU Yi, TANG Liping, WANG Meijuan, OU Yuanzhu, YU Xiaoxuan, LI Qing. IFCC Secondary Reference Measurement Procedure for 4 HbA1c determination systems [J]. Laboratory Medicine, 2019, 34(5): 443-446. |
| [13] | JIN Yuewen, YUE Chaoyan, YING Chunmei. Roles of glycated hemoglobin A1c and glycated albumin in screening gestational diabetes mellitus among elderly pregnant women [J]. Laboratory Medicine, 2018, 33(4): 312-315. |
| [14] | TANG Liping, OU Yuanzhu, LIU Wenbin, YU Xiaoxuan. Evaluation of 2 HbA1c POCT analyzers based on the results of external quality assessment in Shanghai [J]. Laboratory Medicine, 2018, 33(3): 248-251. |
| [15] | YUE Xiaojing, LI Wei, LI Pingfa. Determination of paraquat in plasma by HPLC-MS/MS [J]. Laboratory Medicine, 2018, 33(2): 132-138. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||